**Table 1**

|  |  |  |  |
| --- | --- | --- | --- |
| **Year**  | **\*CD+SSA** | **\*CD-SSA** | **P-Value** |
|   | N | % | N | % | 0.01 |
| 2004 | 0 | 0.0 | 28231 | 9.3 |  |
| 2005 | 0 | 0.0 | 28835 | 9.5 |  |
| 2006 | 2 | 4.3 | 28785 | 9.5 |  |
| 2007 | 5 | 10.6 | 30321 | 10.0 |  |
| 2008 | 10 | 21.3 | 36702 | 12.1 |  |
| 2009 | 5 | 10.6 | 35451 | 11.7 |  |
| 2010 | 11 | 23.4 | 36814 | 12.1 |  |
| 2011 | 5 | 10.6 | 40365 | 13.3 |  |
| 2012 | 9 | 19.2 | 36997 | 12.2 |  |
|    |
| **Year** | **\*UC+SSA** | **\*UC-SSA** | **P-Value** |
|   | N | % | N | % | 0.001 |
| 2004 | 0 | 0.0 | 16361 | 9.4 |  |
| 2005 | 0 | 0.0 | 16267 | 9.3 |  |
| 2006 | 1 | 2.8 | 16525 | 9.5 |  |
| 2007 | 2 | 5.6 | 17689 | 10.2 |  |
| 2008 | 3 | 8.3 | 21432 | 12.3 |  |
| 2009 | 4 | 11.1 | 20237 | 11.6 |  |
| 2010 | 5 | 13.9 | 21252 | 12.2 |  |
| 2011 | 11 | 30.6 | 23443 | 13.5 |  |
| 2012 | 10 | 27.8 | 20851 | 12.0 |  |

**\*Abbreviations: CD+SSA= Crohn’s Disease with Secondary Systemic Amyloidosis; CD-SSA= Crohn’s Disease without Secondary Systemic Amyloidosis; UC+SSA= Ulcerative Colitis with Secondary Systemic Amyloidosis UC-SSA= Ulcerative Colitis without Secondary Systemic Amyloidosis [Percentages % are of the total number of patients in each category during the study period]**

**Table 2**

|  |  |  |
| --- | --- | --- |
| **Variables** | **Full Cohort** | **Matched Cohort** |
| **CD+SSA****N (%)** | **CD-SSA****N (%)** | ***P-*value** | **CD+SSA** **N (%)** | **CD-SSA****N (%)** | ***P-*value** |
| **N=47** | **N=302548** | **N=44** | **N=88** |
| **Age (Years)**  |   |   | <0.001 |   |   | 0.16 |
|  <21 | 3 (6.4) | 16093 (5.8) | 3 (6.8) | 5 (5.8) |
|  22-35 | 0 | 61947 (22.2) | 0 | 11 (12.8) |
|  36-50 | 6 (12.8) | 71930 (25.8) | 6 (11.4) | 15 (17.4) |
|  51-65 | 19 (40.4) | 66820 (23.9) | 18 (40.9) | 25 (29.1) |
|  66-80 | 14 (29.8) | 44520 (15.9) | 14 (31.8) | 23 (26.7) |
|  >81 | 5 (10.6) | 17757 (6.4) | 4 (9.1) | 7 (8.1) |
| **Gender** |   |   | 0.44 |   |   | 0.80 |
| *Female* | 25 (53.2) | 177612 (58.8) | 24 (54.5) | 46 (52.3) |
| *Male* | 22 (46.8) | 124510 (41.2) | 20 (45.5) | 42 (47.7) |
| **Race** |   |   | 0.83 |   |   | 0.52 |
| *Caucasian* | 36 (90) | 201660 (82.2) | 33 (89.2) | 64 (91.4) |
| *African American* | 3 (7.5) | 25598 (10.4) | 3 (8.1) | 2 (2.9) |
| *Hispanic* | 1 (2.5) | 10206 (4.2) | 1 (2.7) | 1 (1.4) |
| *Asian* | 0 | 1796 (0.7) | 0 | 2 (2.9) |
| *Native American* | 0 | 860 (0.4) | 0 | 0 |
| *Other* | 0 | 5133 (2.1) | 0 | 1 (1.4) |
| **Primary payer** |   |   | 0.03 |   |   | 0.56 |
| *Medicare* | 25 (53.2) | 99706 (33.0) | 23 (52.3) | 41 (46.6) |
| *Medicaid* | 0 | 37992 (12.6) | 0 | 3 (3.4) |
| *Private* | 18 (38.3) | 136184 (45.1) | 17 (38.6) | 40 (45.5) |
| *Self pay* | 3 (6.4) | 16224 (5.4) | 3 (6.8) | 3 (3.4) |
| *No charge* | 0 | 1777 (0.6) | 0 | 0 |
| *Other* | 1 (2.1) | 9940 (3.3) | 1 (2.3) | 1 (1.1) |
| **ATN** | 3 (6.4) | 1448 (0.5) | <0.0001 | 3 (6.8) | 7 (7.9) | 0.81 |
| **CHF** | 10 (21.3) | 15370 (5.1) | <0.0001 | 8 (18.2) | 18 (20.5) | 0.76 |
| **Atrial Fibrillation** | 7 (14.9) | 15947 (5.3) | 0.01 | 6 (13.6) | 12 (13.6) | 1.00 |
| **Cardiomyopathy**  | 13 (27.7) | 4141 (1.4) | <0.0001 | 11 (25.0) | 23 (26.1) | 0.88 |
| **Thrombocytopenia** | 5 (10.6) | 4988 (1.7) | <0.0001 | 5 (11.4) | 10 (11.4) | 1.00 |
| **Severe Sepsis** | 3 (6.4) | 3552 (1.2) | 0.01 | 3 (6.8) | 2 (2.3) | 0.19 |
| **ESRD** | 4 (8.5) | 798 (0.3) | <0.0001 | 4 (9.1) | 8 (9.1) | 1.00 |

**\*CD+SSA= Crohn’s disease with Secondary Systemic Amyloidosis; CD-SSA= Crohn’s Disease without Secondary Systemic Amyloidosis; ATN=Acute Tubular Necrosis; CHF=Congestive Heart Failure; ESRD= End Stage Renal Disease**

**Table 3**

|  |  |  |
| --- | --- | --- |
| **Variables** | **Full cohort** | **Matched Cohort** |
| **UC+SSA** **N (%)** | **UC-SSA** **N (%)** | ***P-*value** | **UC+SSA****N (%)** | **UC-SSA** **N (%)** | ***P-*value** |
| **N=36** | **N=174057** | **N= 35** | **N= 70** |
| **Age (Years)**  |   |   | <0.04 |   |   | 0.37 |
|  <21 | 2 (5.6) | 9170 (5.7) | 2 (5.7) | 5 (7.6) |
|  21-35 | 1(2.8) | 27626 (17.3) | 1 (2.9) | 6 (9.1) |
|  36-50 | 3 (8.3) | 31948 (19.9) | 3 (8.6) | 7 (10.6) |
|  51-65 | 11(30.6) | 36959 (23.0) | 11 (31.4) | 9 (13.6) |
|  66-80 | 13 (36.1) | 35782 (22.3) | 13 (34.3) | 27 (40.9) |
|  >81 | 6 (16.6) | 18946 (11.8) | 6 (17.1) | 12 (18.2) |
| **Gender** |   |   | 0.44 |   |   | 0.68 |
| *Female* | 19 (52.8) | 80436 (46.30) | 19 (54.3) | 35 (50.0) |
| *Male* | 17 (47.2) | 93299 (53.70) | 16 (45.7) | 35 (45.7) |
| **Race** |   |   | 0.19 |   |   | 0.21 |
| *Caucasian* | 22 (71.0) | 114728 (79.7) | 21 (70.0) | 53 (86.9) |
| *African American* | 6 (19.3) | 12297 (8.5) | 6 (20.0) | 5 (8.2) |
| *Hispanic* | 1 (3.2) | 10482 (7.3) | 1 (3.3) | 2 (3.3) |
| *Asian* | 0 | 1972 (1.4) | 0 | 0 |
| *Native American* | 0 | 580 (0.4) | 0 | 0 |
| *Other* | 2 (6.5) | 3963 (2.7) | 2 (6.7) | 1(1.7) |
| **Primary payer** |   |   | 0.09 |   |   | 0.72 |
| *Medicare* | 20 (55.56) | 64316 (37.02) | 19 (54.3) | 44 (62.9) |
| *Medicaid* | 3 (8.33) | 15531 (8.94) | 3 (8.5) | 5 (7.1) |
| *Private* | 10 (27.78) | 78992 (45.47) | 10 (28.5) | 17 (24.3) |
| *Self pay* | 1 (2.78) | 7718 (4.4) | 1 (2.9) | 0 |
| *No charge* | 1 (2.78) | 924 (0.53) | 1 (2.9) | 1 (1.4) |
| *Other* | 1 (2.78) | 6259 (3.60) | 1 (2.9) | 3 (4.3) |
| **Hyperlipidemia** | 12 (33.3) | 31663 (18.2) | 0.02 | 11 (31.4) | 20 (28.6) | 0.76 |
| **Hypothyroidism** | 7 (19.4) | 15587 (9.0) | 0.03 | 7 (20.0) | 11 (15.7) | 0.58 |
| **ATN** | 4 (11.1) | 1390 (0.8) | <0.0001 | 4 (11.4) | 8 (11.4) | 1.00 |
| **C. Diff**  | 5 (13.9) | 9948 (5.7) | 0.03 | 5 (14.3) | 8 (11.4) | 0.67 |
| **CHF** | 10 (27.8) | 12595 (7.2) | <0.0001 | 10 (28.6) | 19 (27.1) | 0.88 |
| **Atrial Fibrillation** | 7 (19.4) | 14217 (8.2) | 0.01 | 7 (14.3) | 10 (20.0) | 0.45 |
| **Cardiomyopathy**  | 9 (25) | 2976 (1.7) | <0.0001 | 9 (25.7) | 18 (25.7) | 1.00 |
| **Severe Sepsis** | 3 (6.4) | 3552 (1.2) | 0.01 | 3 (8.6) | 8 (11.4) | 0.65 |
| **CKD III** | 5 (13.9) | 2303 (1.3) | <0.0001 | 4 (11.4) | 8 (11.4) | 1.00 |
| **ESRD** | 6 (16.7) | 443 (0.3) | <0.0001 | 6 (17.1) | 12 (17.1) | 1.00 |

**\*UC+SSA= Ulcerative Colitis with Secondary Systemic Amyloidosis; UC-SSA= Ulcerative Colitis without Secondary Systemic Amyloidoisis; ATN=Acute Tubular Necrosis; C. Diff= Clostridium difficile infection; CHF=Congestive Heart Failure; CKD III= Chronic Kidney Disease Stage III; ESRD= End Stage Renal Disease**

 **Table 4:**

|  |  |  |
| --- | --- | --- |
| **Variables** | **Full Cohort Prematch** | **Matched Cohort** |
| **\*CD+SSA****N (%)** | **\*CD-SSA****N (%)** | ***P-*value** | **\*CD+SSA** **N (%)** | **\*CD-SSA****N (%)** | ***P-*value** |
| **Mortality** | 3 (6.4) | 2873 (1.0) | 0.0001 | 3 (6.8) | 2 (2.3) | 0.20 |
| **Variables** | **Full Cohort Prematch** | **Matched Cohort** |
| **\*UC+SSA** **N (%)** | **\*UC-SSA** **N (%)** | ***P-*value** | **\*UC+SSA****N (%)** | **\*UC-SSA** **N (%)** | ***P-*value** |
| **Mortality** | 6 (16.7) | 3676 (2.1) | <0.0001 | 6 (17.1) | 5 (7.1) | 0.11 |

**\* CD+SSA=Crohn’s Disease with Amyloidosis; CD-SSA=Crohn’s Disease without Amyloidosis; UC+SSA = Ulcerative colitis with Amyloidosis; UC-SSA=Ulcerative Colitis without Amyloidosis; ± Standard deviation**